Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04022876 · ClinicalTrials.gov registry record · Phase 1
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
A Phase 1 study, sponsored by Aileron Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT04022876 is a Phase 1 study that was terminated before completion, run by Aileron Therapeutics. The registered enrollment target is 35 participants.
The verdict
NCT04022876, a Phase 1 study, was terminated before completion, sponsored by Aileron Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is a Phase 1b, multicenter, 2-part study of ALRN-6924 for the prevention of chemotherapy-induced side effects. Part 1 SCLC is an open-label, multicenter study of ALRN-6924 for the prevention of chemotherapy-induced side effects in patients with p53-mutated ED SCLC undergoing 2nd-line treatment with topotecan. (Part 1 has completed enrollment). Part 2 NSCLC is a randomized, double-blind, placebo-controlled, multicenter study of ALRN-6924 for the prevention of chemotherapy-induced side effects in patients with p53-mutated advanced NSCLC of adenocarcinoma histology receiving 1st-line treatment with carboplatin plus pemetrexed with or without immunotherapy.
Interventions
- DRUG Carboplatin
- DRUG Placebo
- DRUG Pemetrexed
- DRUG ALRN-6924
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2019-09-03 |
| Est. Completion | 2022-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04022876
The ClinicalTrials.gov registry entry for NCT04022876 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aileron Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT04022876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04022876 about?
NCT04022876 is a clinical study titled "A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)". This is a Phase 1b, multicenter, 2-part study of ALRN-6924 for the prevention of chemotherapy-induced side effects. Part 1 SCLC is an open-label, multicenter study of ALRN-6924 for the prevention of chemotherapy-induced side effects in patients with p53-mutated ED SCLC undergoing 2nd-line treatment...
What is the current status of trial NCT04022876?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2019-09-03. Estimated completion is 2022-08-30.
What interventions are being tested in trial NCT04022876?
The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Pemetrexed (DRUG), ALRN-6924 (DRUG).
Who is sponsoring clinical trial NCT04022876?
This trial is sponsored by Aileron Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.